Oskar Bergengren
Specialist physician at Institutionen för kirurgiska vetenskaper; Urologkirurgi
- E-mail:
- oskar.bergengren@uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 70, 1 tr
751 85 UPPSALA - Postal address:
- Akademiska sjukhuset, ingång 70, 1 tr
751 85 UPPSALA
More information is available to staff who log in.
Publications
Recent publications
- Short term outcomes after robot assisted and open cystectomy- A nation-wide population-based study (2023)
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review (2023)
- Active surveillance should be considered for select men with Grade Group 2 prostate cancer (2023)
- Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients-A Nationwide Population-based Study (2022)
- Watch out for sticky diagnosis bias in older men with prostate cancer (2022)
All publications
Articles
- Short term outcomes after robot assisted and open cystectomy- A nation-wide population-based study (2023)
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review (2023)
- Active surveillance should be considered for select men with Grade Group 2 prostate cancer (2023)
- Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients-A Nationwide Population-based Study (2022)
- Watch out for sticky diagnosis bias in older men with prostate cancer (2022)
- Surgeon volume and patient-reported urinary incontinence after radical prostatectomy (2022)
- Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths (2022)
- Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort (2021)
- Changes in lifestyle among prostate cancer survivors (2020)
- PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing (2020)
- Determinants for choosing and adhering to active surveillance for localised prostate cancer (2019)
- Satisfaction with Care Among Men with Localised Prostate Cancer (2018)
- The benefit and harm of prostate specific antigen driven diagnostic activity, a 20-year nationwide population-based evaluation